🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⁦Joseph Mikhael⁩ led #myeloma support group leaders through top 10 research questions. So much promise on the horizon. #mmsm

Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort | Blood Cancer Journal ⁦Aditi Shastri, MD⁩ nature.com/articles/s4140…

Relapsed/refractory multiple myeloma care is advancing with innovative therapies and treatment sequencing strategies. This podcast explores how these advancements are improving outcomes for patients and shaping the future of RRMM care. Listen now: bit.ly/3MKu40i

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development #mmsm #bmtsm Sagar Lonial MD Blood Cancer Journal nature.com/articles/s4140…

In our study just published in Blood Cancer Journal Outdoor Air Pollution(OAP) , particularly PM2.5 was associated with a trend towards worse survival in #multiplemyeloma patients treated in a historically redlined area - Bronx, NY. EinsteinSCI Montefiore Health System Albert Einstein College of Medicine - Official

FDA committee advisors voted negatively on the approval of blenrep with bortezomib and dexamethasone and with pomalidomide and dexamethasone. Find out what this decision means for myeloma patients. #mmsm healthtree.org/myeloma/commun…

Peter M. Voorhees, MD, shares key insights from #ASCO25, specifically in the multiple myeloma space. #mmsm | Levine Cancer hubs.li/Q03x7HY70

Myeloma can be cured in some patients and these numbers will increase with current therapist onlinelibrary.wiley.com/doi/10.1002/aj…

🧵 MAIA Study Update: 5-Year Outcomes in NDMM (Transplant-Ineligible) 📄 Facon et al., Leukemia (2025) 💊 D-Rd = Daratumumab + Lenalidomide + Dexamethasone 👇 For clinicians, here’s what you need to know: 1️⃣ Superior PFS & OS with D-Rd 🛡️ 📈 Median PFS:   • D-Rd: 61.9 mo   •

#Myeloma Paper of the Day: Residual disease assessed w/ whole body MRI per MY-RADS protocol linked to shorter PFS (median 24 vs. 42 months) and OS (median 47 months vs. NE) in newly diagnosed or at first relapse patients undergoing first ASCT: pubmed.ncbi.nlm.nih.gov/40675973/. #mmsm

Patient panel discussion at the #SGLS w/the #IMF #mmsm We learn so much from each other.

Panelists discuss the unmet need for effective therapies in early-relapse multiple myeloma, where patients have exhausted standard treatments but do not yet qualify for bispecific therapies or CAR T cells. #mmsm | Binod Dhakal cancernetwork.com/view/later-r-r…

Autologous CAR T-cell therapies derived from patients through leukapheresis have proven effective in hematologic malignancies, but limitations exist. Learn more: hubs.li/Q03x6k1_0

The #MyelomaMinute is out! Your top source of myeloma news. This week we feature how access to a long-term #myeloma specialist is integral to care, ODAC votes, upcoming events & Dr. Joe breaks down the top 10 myeloma breakthroughs from ASCO & EHA. my.myeloma.org/webmail/107765…

Borrowed this image from Cameno’s CEO — we’re witnessing the trispecific revolution unfold! 💥🧬 #Biotech #TrispecificAntibodies #NextGenTherapies #MedEd #USMIRC USMIRC News OncoAlert #myeloma #MedTwitter #MedEd

We're LIVE on Facebook for a Q&A session with IMF CMO Dr. Joe Mikhael, SparkCures founder Brian McMahon & #myeloma patient advocate Thomas Goode! Join us for a breakdown of #myeloma clinical trials & a chance to ask YOUR questions live. mmsm.link/3Tp7uxw #mmsm

We’re all in this together and Robin Tuohy helps empower us all.

Next-generation antibodies are undergoing evaluation with modest success, with several abstracts evaluating trispecific antibodies across cancer settings being presented at #ASCO25. Read the full article: hubs.li/Q03xw8Pf0

Check our recent work UAMS Myeloma Center published Blood Advances : Prognostic Impact of Focal Lesion Location and Persistence in Multiple Myeloma: Insights from Serial PET/DWI Imaging #mmsm ➡️ashpublications.org/bloodadvances/… n= 243 multiple myeloma patients followed 9.9 years with serial

Excited to give a talk on zevor-cel and other novel CAR-T in MM; “Academic Exchange” Shanghai,China! ⁦Medical College of Wisconsin⁩ ⁦MCW Cancer Center⁩